NCT01515579View on ClinicalTrials.gov

Comparison of Two Liraglutide Formulations in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

22

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

June 30, 2006

Study Completion Date

June 30, 2006

Conditions

DiabetesHealthy

Interventions

DRUG

liraglutide

One single dose of 6.25 mg/mL administered subcutaneously

DRUG

liraglutide

One single dose of 6.0 mg/mL administered subcutaneously

Trial Locations (1)

221 85

Lund

Sponsors

Lead Sponsor

Novo Nordisk A/S

All Listed Sponsors

lead

Novo Nordisk A/S

INDUSTRY